Rising adoption of immunotherapy and growing demand for proactive peanut allergy management are supporting market expansion.

Rockville, Maryland – October 15, 2026 — The global peanut allergy treatment market is projected to grow from USD 0.67 billion in 2026 to USD 2.01 billion by 2036, registering a compound annual growth rate (CAGR) of 11.6% over the forecast period, according to Fact.MR. Increasing peanut allergy prevalence, advances in desensitization therapies, and broader access to specialized allergy care are shaping the market's growth outlook.

Get detailed market forecasts, competitive benchmarking, and pricing trends: 

KEY MARKET TAKEAWAYS

• Market Valuation: USD 0.67 billion in 2026, projected to reach USD 2.01 billion by 2036.
• Growth Rate:6% CAGR from 2026 to 2036.
• Leading Segment: Epinephrine is expected to account for 47.0% of the drug class segment in 2026.
• Fastest-Growing Country: The United States is projected to grow at a 12.5% CAGR, followed by China at 12.0%.
• Core Growth Driver: Increasing demand for emergency allergy management and immunotherapy-based desensitization treatments.

INDUSTRY SHIFTS & MARKET DYNAMICS

The peanut allergy treatment market is evolving as healthcare providers expand their focus beyond emergency response toward therapies designed to reduce patients' sensitivity to peanut allergens. Epinephrine remains central to the management of severe allergic reactions, sustaining demand for auto-injectors and other injectable formulations. At the same time, oral, epicutaneous, and sublingual immunotherapy approaches are broadening the treatment landscape. Growing clinical evidence supporting early intervention, particularly in pediatric populations, is encouraging interest in structured desensitization programs. These developments are creating opportunities for pharmaceutical manufacturers to develop treatment options that address both acute allergic reactions and longer-term allergy management.

However, market expansion depends on treatment accessibility, patient adherence, clinical supervision, and reimbursement arrangements. Immunotherapy protocols can require extended treatment periods and carefully managed dose escalation, making consistent participation challenging for some patients and caregivers. The risk of adverse allergic reactions during desensitization also requires appropriate medical oversight. In markets where insurance coverage for newer therapies remains uncertain, treatment costs may limit adoption. Pharmaceutical companies are therefore focusing on alternative delivery formats, clinical evidence generation, and market-access strategies to improve the availability of peanut allergy treatments. Regional growth will also depend on allergy awareness, diagnostic capacity, specialist networks, and the development of healthcare infrastructure.

REGIONAL MARKET SUMMARY

The United States is projected to record the fastest growth among the featured country markets, with China and Japan also showing strong expansion prospects. Germany and India represent additional opportunities as healthcare infrastructure, allergy awareness, and access to specialized treatments develop.

ANALYST INSIGHTS

"The peanut allergy treatment market is undergoing a structural shift from reactive emergency management toward proactive desensitization therapy," stated Shambhu Nath Jha, Principal Consultant at Fact.MR. "Companies investing in alternative immunotherapy delivery formats and securing reimbursement coverage across major markets will be better positioned to address evolving treatment needs and capture future growth opportunities."

Unlock 360° insights for strategic decision making and investment planning: 

FREQUENTLY ASKED QUESTIONS

Q: What is the projected size of the peanut allergy treatment market by 2036?

A: Fact.MR projects the global market to reach USD 2.01 billion by 2036, increasing from USD 0.67 billion in 2026 at a CAGR of 11.6%.

Q: Which segment holds the leading market share?

A: Epinephrine is expected to account for 47.0% of the drug class segment in 2026. Injectable treatments are projected to represent 62.0% of the route-of-administration segment.

Q: Which country exhibits the highest growth rate?

A: The United States is projected to record the highest growth among the reported country markets, at a CAGR of 12.5% through 2036.

Q: What factors are driving market growth?

A: Rising peanut allergy prevalence, regulatory progress in immunotherapy, clinical evidence supporting early intervention, and expanding access to specialized allergy care are key growth drivers.

Q: What challenges could constrain market expansion?

A: Extended treatment protocols, adherence difficulties, risks associated with desensitization, and uncertainty around reimbursement for newer therapies may limit adoption.

Explore More Related Studies Published by Fact.MR Research

Familial Hypercholesterolemia Treatment Market

Smart Implants Market

About Fact.MR

Fact.MR is a market research and consulting firm providing syndicated research, customized research, investment research, and market intelligence across a broad range of industries. Its research coverage includes food and beverage, healthcare, pharmaceuticals, biotechnology, consumer products, chemicals and materials, technology, industrial goods, and packaging.

Fact.MR provides market intelligence designed to help organizations understand market dynamics, emerging opportunities, competitive developments, and changing industry requirements.

Media Contact

Fact.MR
Email: sales@factmr.com
Phone: +1 (628) 251-1583
Website: www.factmr.com